Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

scientific article published on 21 March 2018

Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1055/S-0044-101614
P932PMC publication ID5862553
P698PubMed publication ID29576630

P50authorSara BruckerQ63345510
Peter A. FaschingQ64005064
Matthias W. BeckmannQ72940290
Peyman HadjiQ112631966
Andreas SchneeweissQ37074948
Michael P. LuxQ37372079
P2093author name stringDiethelm Wallwiener
Volkmar Müller
Johannes Ettl
Achim Wöckel
Markus Wallwiener
Hans Tesch
Wolfgang Janni
Diana Lüftner
Andreas D Hartkopf
Tanja N Fehm
Florin-Andrei Taran
Florian Schütz
Erik Belleville
Friedrich Overkamp
Hans-Christian Kolberg
Naiba Nabieva
P2860cites workRANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.Q39670403
Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection MethodsQ41011976
Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patientsQ42013702
Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.Q42236299
Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factorsQ42599064
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysisQ44896647
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentQ45060789
Association analysis identifies 65 new breast cancer risk loci.Q45979098
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancerQ46103372
Body mass index and breast cancer survival: a Mendelian randomization analysisQ46115524
Associations Between Cancer Predisposition Testing Panel Genes and Breast CancerQ46782579
Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association ConsortiumQ47190168
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.Q50089754
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.Q50866974
Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physiciansQ84897741
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breastQ86050224
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSQ28584533
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancerQ29417100
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trialsQ30982699
Breast Cancer Risk - Genes, Environment and ClinicsQ34201805
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancerQ34996647
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkQ35054455
19p13.1 is a triple-negative-specific breast cancer susceptibility locusQ35871567
RAD51B in Familial Breast CancerQ36009422
The contributions of breast density and common genetic variation to breast cancer riskQ36137764
Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian RandomizationQ36276540
Prediction of breast cancer risk based on profiling with common genetic variantsQ36583004
Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer riskQ36600605
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancerQ36859142
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.Q37130218
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 RegulationQ37342144
Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancerQ37374245
RANKL/RANK control Brca1 mutation-driven mammary tumorsQ37457304
Breast Cancer Risk - From Genetics to Molecular Understanding of PathogenesisQ37660589
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancerQ37706111
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.Q38393045
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapyQ38439080
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer RegistryQ38606464
Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients.Q38636290
Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant ChemotherapyQ38699879
BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast CancerQ38914005
Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatmentQ39046820
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationQ39348799
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC CarriersQ39437211
P433issue3
P304page(s)246-259
P577publication date2018-03-21
P1433published inGeburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die PraxisQ26841999
P1476titleUpdate Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.
P478volume78

Reverse relations

cites work (P2860)
Q90285490Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study
Q61795805Mechanisms of Metastasis and Cell Mobility – The Role of Metabolism
Q58101133Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Q90547034RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women
Q61814603Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Q52632717Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.
Q59335358Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
Q59335362Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
Q64102991Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice
Q58587476[TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes]

Search more.